Targeted Genetics Corporation' Partner Celladon Corporation Reports 12 Month Follow Up Data from Phase 2 Clinical Trial of Patients Treated With MYDICAR(R)
SEATTLE--(BUSINESS WIRE)--Targeted Genetics Corporation (Pink Sheets: TGEN.PK) (“Company”) announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.